Literature DB >> 12147403

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

Eric Boersma, Robert A Harrington, David J Moliterno, Harvey White, Maarten L Simoons.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12147403     DOI： 10.1016/s0140-6736(02)09532-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Acute stent thrombosis during percutaneous coronary intervention. Treatment with tirofiban.

Authors:  U Canpolat; H Sunman; H Yorgun; E Atalar
Journal:  Herz       Date:  2011-09-18       Impact factor: 1.443

3.  Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative.

Authors:  Daniel W Mudrick; Anita Y Chen; Matthew T Roe; L Kristin Newby; W Brian Gibler; E Magnus Ohman; Eric D Peterson; Karen P Alexander
Journal:  Am Heart J       Date:  2010-12       Impact factor: 4.749

4.  Antiplatelet pretreatment does not increase hematoma volume in experimental intracerebral hemorrhage.

Authors:  Arne Lauer; Frieder Schlunk; Elizabeth M Van Cott; Helmuth Steinmetz; Eng H Lo; Christian Foerch
Journal:  J Cereb Blood Flow Metab       Date:  2011-03-09       Impact factor: 6.200

Review 5.  Acute coronary syndromes in women and men.

Authors:  Neha J Pagidipati; Eric D Peterson
Journal:  Nat Rev Cardiol       Date:  2016-06-03       Impact factor: 32.419

6.  The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.

Authors:  Steen Husted; Stefan K James; Richard G Bach; Richard C Becker; Andrzej Budaj; Magda Heras; Anders Himmelmann; Jay Horrow; Hugo A Katus; Riita Lassila; Joao Morais; José C Nicolau; Ph Gabriel Steg; Robert F Storey; Daniel Wojdyla; Lars Wallentin
Journal:  Eur Heart J       Date:  2014-03-28       Impact factor: 29.983

7.  Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.

Authors:  Michelle L O'Donoghue; Deepak L Bhatt; Gregg W Stone; Ph Gabriel Steg; C Michael Gibson; Christian W Hamm; Matthew J Price; Jayne Prats; Tiepu Liu; Efthymios N Deliargyris; Kenneth W Mahaffey; Harvey D White; Robert A Harrington
Journal:  Circulation       Date:  2016-01-19       Impact factor: 29.690
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.